All In Biotech

Drug Trial Radar · NCT02960893

Trial in Adult Participants With Spinocerebellar Ataxia (SCA)

A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult Participants With Spinocerebellar Ataxia

Last checked: Nov 19, 2026Latest source record: Oct 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 141 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

141

Actual

Start

Dec 15, 2016

Primary completion

Aug 18, 2017

Study completion Sep 20, 2024

Sponsor

Lead sponsor
Biohaven Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Nov 10, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study was to compare the efficacy of BHV-4157 (Troriluzole) 140 milligrams (mg) once daily versus placebo after 8 weeks of treatment in participants with spinocerebellar ataxia (SCA).

Conditions

  • Spinocerebellar Ataxias
  • Spinocerebellar Ataxia Genotype Type 1
  • Spinocerebellar Ataxia Genotype Type 2
  • Spinocerebellar Ataxia Genotype Type 3
  • Spinocerebellar Ataxia Genotype Type 6
  • Spinocerebellar Ataxia Genotype Type 7
  • Spinocerebellar Ataxia Genotype Type 8
  • Spinocerebellar Ataxia Genotype Type 10

Interventions

  • TroriluzoleDrug

    Randomization Phase: Neat (i.e., drug substance without excipients); loose filled capsule.

  • PlaceboDrug

    Drug: Placebo Randomization Phase: Matching placebo loose filled capsule.

  • TroriluzoleDrug

    OLE phase: Neat capsule or formulated capsule (i.e., drug substance with excipients).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Total Score on the Scale for the Assessment and Rating of Ataxia (SARA) at Randomization Phase Week 8Time frame: Baseline, Randomization Phase Week 8

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • St. Joseph's Hospital and Medical Center

    Phoenix, Arizona

  • CNS Trial

    Long Beach, California

  • University of California, Los Angeles

    Los Angeles, California

  • University of California, San Francisco

    San Francisco, California

  • University of Colorado Denver

    Denver, Colorado

  • University of Florida

    Gainesville, Florida

  • University of South Florida

    Tampa, Florida

  • Emory University

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • University of Chicago

    Chicago, Illinois

  • Johns Hopkins University

    Baltimore, Maryland

  • Harvard University (Massachusetts General Hospital)

    Boston, Massachusetts

  • Harvard University (Beth Israel Deaconess Medical Center)

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Columbia University

    New York, New York

  • University of Rochester Medical Center

    Rochester, New York

  • University of Texas Southwestern

    Dallas, Texas

  • Houston Methodist Research Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.